Preliminary screening of Pioglitazone and Diosgenin novel combination for Alzheimer’s disease

The pathophysiology of Alzheimer’s disease (AD) is a complex phenomenon which mediating through Aβ plaque formation and neurofibrillary tangles. Since, last few decades preclinical and clinical research evidences strengthen the elucidation of underlying causes in disease progression. The ongoing studies are mainly focused to screen the potential clinical candidates which turndown the neurodegeneration or delaying in AD progression. Considering the complicated etiopathogenesis of AD, the therapies which target the multiple molecular pathways of AD is required to potentiate the treatment and which in turn regulates the AD related complications. Diosgenin (DG), a natural steroidal saponin which has proven for an antioxidant, neuroprotective effects, and Pioglitazone is a peroxisome proliferator-activated receptor-γ agonist that has been found to be effective in treating several neuropathies. DG and Pioglitazone combination may be a successful novel approach in treating AD and other neurodegenerative disorders; in the present study, we were targeted the neuro-inflammatory pathways with Pioglitazone and DG to evaluate the neuroprotective potential especially in AD like condition. Overall, the research findings revealed the possible therapeutic benefits with novel combination and it was notably down-regulated the cytokine storm and Aβ plaque formation.

[1]  S. Murugesan,et al.  Identification of Papain-Like Protease inhibitors of SARS CoV-2 through HTVS, Molecular docking, MMGBSA and Molecular dynamics approach , 2021, South African Journal of Botany.

[2]  T. Govender,et al.  Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. , 2021, European journal of medicinal chemistry.

[3]  A. Justin,et al.  Glitazones Activate PGC-1α Signaling via PPAR-γ: A Promising Strategy for Antiparkinsonism Therapeutics. , 2021, ACS chemical neuroscience.

[4]  J. Antony,et al.  Neuroprotective role of Diosgenin, a NGF stimulator, against Aβ (1–42) induced neurotoxicity in animal model of Alzheimer’s disease , 2021, Metabolic Brain Disease.

[5]  A. Justin,et al.  Rational Design, Synthesis, and In Vitro Neuroprotective Evaluation of Novel Glitazones for PGC-1α Activation via PPAR-γ: a New Therapeutic Strategy for Neurodegenerative Disorders , 2019, Neurotoxicity Research.

[6]  Xinhua Wang,et al.  LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as an in vitro model for Alzheimer’s disease , 2019, Bioscience, biotechnology, and biochemistry.

[7]  N. Ip,et al.  Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. , 2018, ACS chemical neuroscience.

[8]  Gautam Sethi,et al.  Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review , 2018, Nutrients.

[9]  M. Matsui,et al.  Diosgenin-Rich Yam Extract Enhances Cognitive Function: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study of Healthy Adults , 2017, Nutrients.

[10]  Li-min Hu,et al.  Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization , 2017, International immunopharmacology.

[11]  E. Gallardo,et al.  Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology , 2016, Journal of analytical methods in chemistry.

[12]  Yueqin Li,et al.  Diosgenin ameliorates gestational diabetes through inhibition of sterol regulatory element-binding protein-1. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  J. Hong,et al.  Diosgenin effectively suppresses skin inflammation induced by phthalic anhydride in IL-4/Luc/CNS-1 transgenic mice , 2016, Bioscience, biotechnology, and biochemistry.

[14]  J. Connor,et al.  The effects of okra (Abelmoschus esculentus Linn.) on the cellular events associated with Alzheimer’s disease in a stably expressed HFE neuroblastoma SH-SY5Y cell line , 2015, Neuroscience Letters.

[15]  Xi-Long Zheng,et al.  Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1. , 2015, Atherosclerosis.

[16]  K. Sugibayashi,et al.  Effect of liquid crystals with cyclodextrin on the bioavailability of a poorly water-soluble compound, diosgenin, after its oral administration to rats. , 2014, International journal of pharmaceutics.

[17]  Y. Goto,et al.  Diosgenin-induced cognitive enhancement in normal mice is mediated by 1,25D3-MARRS , 2013, Scientific Reports.

[18]  T. Pan,et al.  Osteoprotective effect of Monascus-fermented dioscorea in ovariectomized rat model of postmenopausal osteoporosis. , 2011, Journal of agricultural and food chemistry.

[19]  R. Zweig,et al.  Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response , 2010, Experimental Neurology.

[20]  Jaime Eugenín,et al.  Aging‐dependent changes of microglial cells and their relevance for neurodegenerative disorders , 2010, Journal of neurochemistry.

[21]  Yinlan Zhao,et al.  Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H.Wright in rodents. , 2009, Journal of ethnopharmacology.

[22]  G. Landreth.  Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.

[23]  Federico D. Sacerdoti,et al.  Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).

[24]  T. Klockgether,et al.  Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms , 2006, International Journal of Developmental Neuroscience.

[25]  Suzanne Craft,et al.  Insulin and neurodegenerative disease: shared and specific mechanisms , 2004, The Lancet Neurology.

[26]  V. Papadopoulos,et al.  Identification of naturally occurring spirostenols preventing β-amyloid-induced neurotoxicity , 2004, Steroids.

[27]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[28]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[29]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Kojro,et al.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Shearman,et al.  The Intracellular Component of Cellular 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) Reduction Is Specifically Inhibited by β‐Amyloid Peptides , 1995 .

[32]  B. Winblad,et al.  Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  J. Haxby,et al.  Dementia in Down's syndrome , 1988, Neurology.

[35]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[36]  C. Rhodes,et al.  Stability of diosgenin. , 1968, Journal of pharmaceutical sciences.

[37]  J. Cole,et al.  Use of molecular docking computational tools in drug discovery. , 2021, Progress in medicinal chemistry.

[38]  P. Reddy,et al.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. , 2017, Journal of Alzheimer's disease : JAD.

[39]  D. Cechetto,et al.  The Cerebral Cortex in Neurodegenerative and Neuropsychiatric Disorders : Experimental Approaches to Clinical Issues , 2016 .

[40]  C. Atwood,et al.  A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis. , 2015, Journal of Alzheimer's disease : JAD.

[41]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[42]  P. S. St George-Hyslop,et al.  gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? , 2002, Nature reviews. Neuroscience.

[43]  J. Galloway.  A Review of the , 1901 .